发明名称 |
Chaperonin 10 variants |
摘要 |
The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs). |
申请公布号 |
US8933033(B2) |
申请公布日期 |
2015.01.13 |
申请号 |
US201013500159 |
申请日期 |
2010.10.08 |
申请人 |
CBio Limited |
发明人 |
Naylor Dean Jason;Brown Richard James;Howard Christopher Bruce;De Bakker Christopher John;Stok Jeanette Elizabeth;James Andrew Leigh;Lambert Daniel Scott;Ralston Kylie Jane;Van Heumen Walter Rene Antonius;Ward Linda Allison |
分类号 |
A61K38/00;A61K38/16;C07K1/00;C07K14/47;G01N33/50;A61K48/00 |
主分类号 |
A61K38/00 |
代理机构 |
Ditthavong & Steiner, P.C. |
代理人 |
Ditthavong & Steiner, P.C. |
主权项 |
1. An isolated chaperonin 10 (Cpn10) variant polypeptide derived from human Cpn10 sharing at least 90% sequence identity with a wild-type human Cpn10 polypeptide and comprising an N-terminus extended by two to five additional amino acid residues compared to said wild-type polypeptide, wherein the polypeptide has increased binding affinity for a pathogen-associated molecular pattern (PAMP) compared to the binding affinity of Ala-Cpn10 (SEQ ID NO: 3) for said PAMP, wherein the isolated Cpn10 polypeptide possesses a conserved core antiparallel β-barrel flanked by a β-hairpin roof loop region and a mobile loop region. |
地址 |
Queensland AU |